AmoyDx Collaborates with AstraZeneca to Co-develop HRD Companion Diagnostics for Ovarian Cancer
Xiamen, China, 19th February, 2021 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with AstraZeneca to develop a Homologous Recombination Deficiency (HRD) Companion Diagnostic (CDx) in ovarian cancer.
AmoyDx at WCLC 2020 wrap-up
As a supporter to WCLC 2020, AmoyDx set up a virtual booth with NSCLC product pipeline and sponsored an Industry Symposium with the hot topics of Biomarker Panel testing in Lung Cancer. Prof. Tony Mok (Chairmen), Prof. Koichi Goto and Prof. Caicun Zhou pr
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market
Xiamen, China, December 23, 2020 (12:30 pm) – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepo
AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide
Xiamen, China, 16th November, 2020 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.
Visit AmoyDx at 2020 AMP Virtual Meeting & Expo
The 2020 AMP Virtual Meeting & Expo starts MONDAY and we cannot wait to meet you online. If you do not want to miss the great content shared from AmoyDx, be sure to stop by our virtual booth during November 16th - 20th.
AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award
The EGFR mutation detection method from AmoyDx (Application No.: ZL200910111499.2, Publication No.: CN101608240B) won the Silver Award of the 21st China Patent Award as recently announced by the China National Intellectual Property Administration (CNIPA).